Paragon 28, Inc. (FNA)
After hours:
| Previous close | 7.78 |
| Open | 7.83 |
| Bid | 7.72 x 800 |
| Ask | 7.49 x 1100 |
| Day's range | 7.35 - 7.87 |
| 52-week range | 7.25 - 19.00 |
| Volume | |
| Avg. volume | 617,060 |
| Market cap | 637.896M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance
ENGLEWOOD, Colo., May 08, 2024--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance.
- Business Wire
Paragon 28 to Present at the Bank of America Securities 2024 Healthcare Conference
ENGLEWOOD, Colo., May 02, 2024--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Krissy Wright, Interim CFO, will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024, at 5:00 p.m. Pacific Time / 6:00 p.m. Mountain Time.
- Business Wire
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024
ENGLEWOOD, Colo., April 04, 2024--Paragon 28, Inc. (NYSE: FNA), ("Paragon 28" or "the Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Stephen Deitsch, Chief Financial Officer ("CFO"), has notified the Company of his intent to pursue an opportunity with OrganOx Limited, a commercial stage UK-based medical device company focused on therapeutic applications of isolated organ perfusion. Mr. Deitsch will depart from the Com
